Cardiovascular and metabolic disease : scientific discoveries and new therapies /

Cardiovascular and metabolic diseases remain the number one cause of death in developed countries and their prevalence is increasing rapidly in developing nations. This book brings together the recent information on these disorders and the links that exist between them in order to provide a complete...

Full description

Bibliographic Details
Corporate Author:	Royal Society of Chemistry (Great Britain)
Other Authors:	Adams, James (Editor), Peplow, Philip (Editor), Young, Tim (Editor)
Format:	eBook
Language:	English
Language Notes:	English.
Published:	[Cambridge] : Royal Society of Chemistry, 2015.
Series:	RSC drug discovery series ; 45.
Subjects:	Cardiovascular system > Diseases > Treatment. Cardiovascular system > Diseases. Metabolism > Disorders > Treatment. Metabolism > Disorders. Biological Science Disciplines. Cardiovascular Diseases. Causality. Chemistry, Pharmaceutical. Chemistry. Delivery of Health Care. Disease. Drug Design. Drug Discovery. Environment and Public Health. Epidemiologic Factors. Epidemiologic Methods. Glucose Metabolism Disorders. Health Care Evaluation Mechanisms. Health Care Quality, Access, and Evaluation. Hyperinsulinism. Insulin Resistance. Investigative Techniques. Metabolic Diseases. Metabolic Syndrome. Natural Science Disciplines. Nutritional and Metabolic Diseases. Pharmacology. Probability. Public Health. Quality of Health Care. Risk Factors. Risk. Statistics as Topic. Health & Biological Sciences. Medicine. Diseases & disorders. MEDICAL / Pharmacology. SCIENCE / Life Sciences / Biochemistry. Electronic books.
Online Access:	Connect to the full text of this electronic book

Table of Contents:

Cover; Contents; Introduction; Chapter 1 The Relevance of Biomarkers, Risk Factors and Gene-Environment Interactions in Disease: Scientific Developments and Therapeutic Approaches; 1.1 Introduction; 1.2 Biomarkers of Disease; 1.3 Risk Factors of Disease; 1.4 Gene-Environment Interactions in Disease; 1.5 Drug Development and Targeted Therapies; 1.6 Conclusion; References; Part 1 Obesity; Chapter 2 Molecular Links between Obesity, Hypertension and Metabolic Dysfunction; 2.1 Introduction; 2.2 Consequences of Obesity on Cardiovascular and Metabolic Disease.
2.3 Role of the SNS in Obesity-related Hypertension2.4 Contribution of Leptin and Insulin to Obesity-related Hypertension; 2.5 Role of Pro-opiomelanocortin Neurons; 2.6 Contribution of Neuropeptide Y; 2.7 Contribution of Ghrelin; 2.8 Effects of Obesity Across Generations; 2.9 The Influence of Aversive Stress on Obesity-related Hypertension; 2.10 Conclusions; References; Chapter 3 Discovery of Biomarkers of Obesity; 3.1 Introduction; 3.2 Identifying and Classifying Obese Individuals; 3.2.1 Classifying Obesity in Adults; 3.2.2 Classifying Obesity in Infants and Children.
4.4 The High Fat Food Problem4.5 Why is Dietary Fat a Problem?; 4.6 Alcohol is the Worst Obesogen; 4.7 Fad Foods and Obesity; 4.8 Toxic Fats; 4.9 Bad Carbohydrates, Empty Calories and High Glycemic Index; 4.10 Childhood Obesity; 4.11 Sedentary Lifestyles; 4.12 Why is Exercise so Important?; 4.13 Present Lessons for the Future; References; Chapter 5 Gene-Environment Interactions in Obesity; 5.1 Introduction; 5.2 Definition and Methods Used in the Assessment of Obesity; 5.3 Genetics and Obesity; 5.4 Animal Models and the Genetics of Obesity; 5.4.1 Spontaneous Animal Models of Obesity.
5.4.2 Genetically Engineered Animal Models of Obesity5.5 Genetic Approaches to Studying Human Obesity; 5.6 Epigenetics and Obesity; 5.7 Environmental Genetic Interactions in Obesity; 5.8 Summary; References; Chapter 6 New Drug Design and Therapeutic Development for Weight Reduction: Preclinical Studies and Clinical Trials; 6.1 Obesity and its Metabolic Consequences; 6.1.1 The Strategic and Commercial Landscape of Drug Intervention; 6.2 Preclinical Studies; 6.2.1 CNS Approaches; 6.2.2 Peripheral Approaches; 6.3 Clinical Studies; 6.3.1 Lorcaserin; 6.3.2 Phentermine.